GT Biopharma, Inc. Cash And Cash Equivalents At Carrying Value

• GT Biopharma, Inc. showed an increase of +72.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2009 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2009 to 2025), GT Biopharma, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 426.8%.
• Historical annual values: Fiscal year 2025: $6.81 million | Fiscal year 2024: $3.95 million | Fiscal year 2023: $1.08 million | Fiscal year 2022: $5.67 million | Fiscal year 2021: $8.97 million | Fiscal year 2020: $5.30 million | Fiscal year 2019: $28.0 thousand | Fiscal year 2018: $60.0 thousand | Fiscal year 2017: $576.0 thousand | Fiscal year 2016: $19.0 thousand | Fiscal year 2015: $47.0 thousand | Fiscal year 2014: $855.0 thousand | Fiscal year 2013: $43.0 thousand | Fiscal year 2012: $123.0 thousand | Fiscal year 2012: $61.0 thousand | Fiscal year 2011: $92.0 thousand | Fiscal year 2010: $54.0 thousand | Fiscal year 2009: $1.29 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026